JPRN-jRCTs041180147已完成1 期
Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma - Phase I study of GnP-CRT for BR and UR-LA PDAC
Kishiwada Masashi0 个研究点目标入组 15 人开始时间: 2019年3月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
The RD of nab-paclitaxel in our GnP-CRT protocol was 100 mg/m2 with gemcitabine 600 mg/m2 and 3-dimensional conformal radiotherapy to a total dose of 50.4 Gy/28 fr for patients with locally advanced PDAC.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 85age old（—）
- 性别
- All
入选标准
- •The cases who were diagnosed as Borderline resectable or locally advanced unresectable pancreatic cancer by MDCT and was histologically diagnosed as malignancy/adenocarcinoma by EUS-FNA or cytology of pancreatic juice
排除标准
- •The patients who have the allergy of medication or severe infection
- •The patients who was considered to be inappropriate for this study
研究者
相似试验
已完成
不适用
Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinomapancreatic cancerJPRN-UMIN000030551Mie university15
已完成
1 期
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic CancerPancreatic CancerNCT02283372Washington University School of Medicine30
已完成
1 期
Phase I trial of Gemcitabine plus nab-Paclitaxel for metastatic breast cancerBreast cancerJPRN-UMIN000009067Okayama Univesity Hospital9
已完成
不适用
Phase I/II study of gemcitabine and nab-paclitaxel with radiation therapy in patients with pancreatic cancer.pancreatic cancerJPRN-UMIN000017751Department of Surgery, Keio University School of Medicine30
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24